Bendamustin as second-line therapy in patients with relapsed low grade non-Hodgkin's lymphoma and multiple myeloma;Zur Rezidivtherapie mit Bendamustin bei Patienten mit Non-Hodgkin-Lymphomen von niedrigem Malignitatsgrad und Plasmozytomen

Tumor Diagnostik und Therapie

Volumn 18, Issue 3, 1997, Pages 71-75

  Heider, A ^a   Kress M ^a   Niederle, N ^a  

^a KLINIKUM LEVERKUSEN   (Germany)

Author keywords

bendamustin; lymphoma; multiple myeloma; relapse therapy

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA;

EID: 0030808228     PISSN: 0722219X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Brittinger G, Engelhard M: Clinical and prognosis relevance of the Kiel-classification of non-Hodgkin lymphomas: Verh Dtsch Ges Pathol 76 (1992) 37 - 46
2. Ozegowski W, Krebs D: IMET 3393, γ(1-Methyl-5-bis-(β-chloräthyl)-amino-benzimidazolyl(2))- buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste. Zbl Pharm 110, Heft 10 (1971) 1013 - 1019
3. Brockmann B, Geschke E, Schmidt U M, Ebeling K: Therapieergebnisse und toxische Nebenwirkungen der Kombination Cytostasan®, Adriamycin und Vincristin als "Second line-Therapie" beim metastasierten Mammakarzinom. Geburtsh u Frauenheilk 51 (1991) 1 - 4
4. Ruffert K, Jahn H, Syrbe G, Stauch M, Jorke D, Kühn R: Cytostasan® (Bendamustin) in der Alternativtherapie maligner Lymphome. Z Klin Med 44 (1989) 671 - 674
5. Anger G, Fink R, Fleischer J, Hesse P, Krug K, Raderecht C et al: Vergleichsuntersuchungen zwischen Cytostasan und Cyclophosphamid bei der chronischen Lymphadenose, dem Plasmozytom, der Lymphogranulomatose und dem Bronchialkarzinom. Dt Gesundh-Wesen 30 (1975) 1280 - 1285
6. Bremer K, Roth W: Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas. Tumordiagn. u. Ther. 17 (1996) 1 - 6
7. Huber H, Gattringer C, Lechleitner M. Gyenes T, Frommhold H, Brittinger G et al.: Die Therapie maligner Lymphome. Wiener Klin Wochenschr 95 (1983) 93 - 112
8. Preiss R, Sohr R, Matthias M, Brockmann B, Hüller H: Untersuchungen zur Pharmakokinetik von Bendamustin (Cytostasan®) am Menschen. Pharmazie 40 (1989) 782 - 784
9. Salmon S E, Cassady J R: Plasma cell neoplasms. In: DeVita Jr V T, Hellmann S, Rosenberg S A. (Eds.): Cancer. Principles u. practice of oncology, 3rd edition. J. B. Lippincott Company, Philadelphia, Grand Rapids, New York, St. Louis, San Francisco, London, Sydney, Tokyo (1989) 1853 - 1895
10. Dejager R L, Krutchik AN: Multiple Myeloma. In: Randomized trials in cancer: A critical review by sites. Eds. Slevin M L, Staquet M J. Raven Press New York (1989) 75 - 89
11. Hiddemann W, Unterhalt M, Polt C, Wörmann B, Sanford D, Freund M et al.: Fludarabine single agent therapy for relapsed lowgrade non-Hodgkin's lymphomas: A phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Sem. Oncol. 20, Suppl. 7 (1993) 28-31
12. WHO handbook for reporting results of cancer treatment, No. 48 (1979), WHO Offset Publication, Geneva
13. Palmer M, Belch A, Brox L, Pollack E, Koch M: Are the current criteria for response useful in the management of multiple myeloma? J. clin. Oncol. 5 (1987) 1373 - 1377
14. Freedman A S, Nadler L M: Which patients with relapsed non Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? J. clin. Oncol. 11 (1993) 1841 - 1843
15. Knospe W H, Loeb V, Hugulex C M: Biweekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer 33 (1974) 555 - 562
16. French Cooperative Group on Chronic Lymphocytic Leukemia . Effectiveness of "CHOP" regimes in advanced untreated chronic lymphocytic leukemia. Lancet I (1986) 1346 - 1349
17. Montserrat E, Rozmanc C: Current approaches to the treatment and management of chronic lymphocytic leukemia. Drugs 47 Suppl 6 (1994) 1 - 9
18. Hiddemann W, Unterhalt M, Koch P, Nahler M, Herrmann R: New aspects in the treatment of advanced low-grade Non-Hodgkin lymphomas: PnM vs COP followed by IFα vs observation only - A preliminary up-date of the German low-grade lymphoma study group. Sem. Hemat. 31 Suppl 3 (1994) 32 - 35
19. Alexanian R, Barlogie B, Tucker S: VAD-based regimes as primary treatment for multiple myeloma. Am J. Hematol. 33 (1990) 86 - 89
20. Barlogie B, Epstein J, Selvanayagam P, Alexanian R: Plasma cell myeloma - new biological insights and advance in therapy. Blood 73 (1989) 865 - 879
21. Herold M, Keinert K, Anger G, Eschenburg H, Richter P, Fink R: Risk-adapted combined radiotherapy and chemotherapy for Hodgkin's disease - results of a pilot study. Onkologie 15 (1992) 502 - 505
22. Höche D, Wutke K, Anger G, Herold M, Kästner R . Zur Therapie der fortgeschrittenen Lymphogranulomatose. Z. Klin. Med. 40 (1985) 411 - 414
23. Junghanß C, Heußner P, Krammer-Steiner B, Decker S, Petershofen E, Freund M: Dexa-BID, a bendamustinehydrochloride containing regimen for refractory and relapsed low grade Non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Ann. Hematol. Vol 73, Suppl II (1996), Abstract 536
24. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S: Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anti-Cancer Drugs 7 (1996) 415 - 421
25. Reck M, Haering B, Gatzemeier U, Koschel G, Kaukel E: Chemotherapie des fortgeschrittenen kleinzelligen und nicht kleinzelligen Bronchialkarzinoms mit Bendamustin - Eine Phase II Studie. Pneumologie 51 (1997) Abstract P 260
26. Bremer K: Bendamustin, ein effektives Zytostatikum bei Alkylantien-resistenten Non-Hodgkin-Lymphomen. Deutscher Krebskongreß 1996 Abstract P 3.3.13
27. The French Cooperative Group on CLL, Johnson S, Smith Ag, Löffler H, Ösby E. Juliusson G et ai.: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukaemia. Lancet 347 (1996) 1432 - 1438